Introduction: Angiotensin IV is one of the biologically active peptides of the renin-angiotensin system. Limited data suggests that this hexapeptide could contribute to cancer development and/or progression. Materials and methods: Using the MTT reduction assay as an indicator of cell viability, and the bromodeoxyuridine incorporation assay as an indicator of cell proliferation, the influence of Angiotensin IV was evaluated on two human prostate cancer lines: androgen-dependent (LNCaP) and androgen-independent (DU-145). The potential effect of Angiotensin IV classic angiotensin receptors was examined by using the selective antagonists losartan and PD123319. Finally, the changes in expression levels of AT1 and AT2 receptors were compared, before and after angiotensin treatment. Results: Angiotensin IV caused significant changes in cell viability and proliferation in LNCaP cells but not in DU-145. It was found that AT2 receptor blocker (PD123319) was able to diminish the suppressor effect of Angiotensin IV on bromodeoxyuridine incorporation into the DNA of androgen-dependent prostate cancer cells. Simultaneously, it was reported that Angiotensin IV is the factor that modulates the density of AT1 and AT2 receptors in prostate cancer cells. Conclusions: These findings suggested that Angiotensin IV can modulate tumour cell proliferation in the early stage of androgen-dependent prostate cancer. The effect might be promoted by the change of the angiotensin receptor level.
Introduction
The results of previous investigations have revealed that the local renin-angiotensin system (RAS) has been identified in many organs and tissues including the prostate. Expression of all elements of the system has been noted in both human and rat prostate cells. [1] [2] [3] [4] [5] Moreover, the changes in selected components of the RAS have been observed in pathological states of the prostate, like benign prostatic hyperplasia or prostate cancer. These changes lead to the expression of AT1 receptor, ACE enzyme and an increase in the local concentration of Angiotensin II (Ang II) or angiotensinogen. [6] [7] [8] [9] These latest studies suggested that the RAS may be an important regulator of prostatic function.
Certainly, Ang II is one of the most important effector peptides of the circular and local RAS. In addition, it is known that many tissues are capable of producing other peptides belonging to the angiotensin family, which may also mediate specific effects: autocrine, paracrine and intracrine. A good example is Angiotensin IV (Ang IV), a hexapeptide formed from Ang II by deletion of the two N-terminal amino acids (Asp and Arg). This peptide, due to its wide spectrum of action, has aroused increasing interest in recent years. For instance, Ang IV regulates not only blood flow and memory retention but also inflammation, cell proliferation and differentiation. [10] [11] [12] [13] Ang IV can mediate biological effects by interaction with the classic receptors AT1 and AT2, which belong to the G protein-coupled receptor family (GPCR), and through binding to the receptor AT4, which has been identified as the enzyme insulin regulated aminopeptidase (IRAP). It is known that Ang IV appears to affect the modulation of certain mitogen-activated protein kinases (MAPKs), protein tyrosine kinases (PTKs) and NF-β signal activation. Furthermore, Ang IV increases cyclic guanosine monophosphate (cGMP) production and induces changes in DNA and RNA synthesis. However, the mechanism of action of Ang IV and its physiological significance is still debated. [11] [12] [13] The aims of this study were to evaluate the effects of Ang IV on cell viability and proliferation in androgendependent and androgen-independent prostate cancer cell lines, as well as to determine the effects of Ang IV on classic angiotensin receptors.
Materials and methods

Cell lines
LNCaP and DU-145 cells were obtained from the American Type Culture Collection (ATCC). LNCaP was cultured in RPMI 1640 medium and DU-145 was cultured in DMEM. Both media were supplemented with inactivated fetal bovine serum (FBS), L-glutamine sodium pyruvate and antibiotics (Life Technologies / Gibco). The cell lines were incubated in a humidified atmosphere of 5% CO2 and 95% air, at 37°C. The relatively fast-growing, androgen-independent cells were passaged twice per week whereas the slow-growing, androgen-dependent cells were passaged only once per week.
Reagents
The Ang IV was purchased from Bachem. The losartan was kindly provided by Prof. Pawlikowski (Medical University of Lodz). The non-peptide AT2 antagonist PD123319 was obtained from Sigma.
MTT test
The prostate cancer cells were plated at a density of 2 × 10 4 cells/well in 96-well plates and were maintained overnight in complete medium. Subsequently, the cells were incubated with various concentrations of Ang IV (0.05-5 nM). After 24 h incubation, culture medium was discarded and 100 μl of MTT (0.5 mg/ml PBS) was added to each well. The MTT-formazan crystals formed were dissolved in 80 μl of DMSO. MTT reduction was measured spectrophotometrically at 570 nm on a BioTek microplate reader. Cell survival (% of control) was calculated in relation to untreated control cells. The control cells were grown under the same conditions, without the addition of Ang IV.
Bromodeoxyuridine (BrdU) test
Cells were seeded in a 96-well flat bottom plate (2×10 3 cells/well) and were maintained overnight in complete medium at 5% CO2, 37°C. The cells were then incubated (24 and 48 h) with Ang IV (0.05-5 nM) in the presence and absence of 5000 nM losartan or PD123319. Finally, BrdU was added to the culture medium in the last hour of incubation, according to the manufacturer's instructions (Millipore). The coloured reaction product was quantified by measuring absorbance at 450 nm on a BioTek microplate reader. Cell proliferation (% of control) was calculated in relation to untreated controls.
Real-time RT-PCR
The prostate cancer cells (passage number between 5 and 10) were exposed to Ang IV (5 nM) for 24 h. Then the total RNA from cells was extracted by using TRIzol reagent and purified with standard phenol: chloroform technique. The quantity of recovered RNA and its purity was determined by reading the absorbance at 260 and 280 nm. Reversetranscriptase synthesis of cDNA was performed on a 10 μg total mass of RNA in a final volume of 50 μl using oligo(dT)15 primer, random hexamer primer and ImProm RTII TM reverse transcriptase (Promega). The thermal conditions of cDNA synthesis were as follows: Incubation at 25°C/5 min and 42°C/60 min, heating at 70°C/15 min. The cDNA libraries were stored at -20°C. Amplification reactions were performed in a final volume of 20 μl including 2 μl cDNA and were detected using SYBR ® Green I and qPCR Core kit for SYBR ® Green I (Eurogentec). Real-time RT-PCR was performed with a Rotor-Gene 3000 (Corbett Research).
The Universal Human Reference RNA (Stratagene), composed of total RNA from 10 human cell lines, was used as a calibrator (5 μg/μl). The relative expression of levels AT1 or AT2 was normalized using the H3F3A, RPLPO and RPS17 genes as an endogenous control. Relative gene expression was calculated with the Roche company guidebook according to the published algorithm. 14 The following sequences of oligonucleotides were used in the experiments: 
Western blotting
The prostate cancer cells (passage number between 5 and 20) were treated with or without Ang IV (5 nM). After 24 h, the cells were washed once in PBS and lysed in 60-100 μl of RIPA buffer supplemented with protease and phosphatase inhibitors (Sigma) for 30 min at 4°C. The lysate was centrifuged at 14,000 rpm for 20 min to remove insoluble material. Protein concentrations were determined by the Bradford Protein Assay Kit (BioRad). For western blot analysis, whole cell lysates were prepared by lysing the prostate cancer cells in Leammli buffer at 95°C for 5 min. The protein samples (30 μg) were separated on a 10% polyacrylamide gel and transferred to nitrocellulose using a Mini-PROTEAN Tetra system (Bio-Rad). Non-specific protein binding sites were blocked using 5% dry milk in TBST buffer for 1 h at room temperature. After blocking, the membrane was incubated overnight at 4°C with primary antibodies: anti-AT1, anti-AT2 or loading control anti-GAPDH (Santa Cruz Biotechnology). The membrane was than incubated in peroxidase-labelled anti-IgG (Sigma) for 1 h at room temperature. The positive band was revealed using Sigma-Fast BCIP/NBT reagent. Quantitative analysis of the blots was measured densitometrically using imaging software for Quantity One Bio-Rad.
Statistical analysis
All statistical analyses were performed using the statistics package StatGraphics Plus 6.0. Statistical significance was assessed by one-way analysis of variance (ANOVA) for repeated measurements followed by the least significant difference (LSD) post hoc tests to determine the extent of the differences. A significance level of 5% was chosen (p<0.05).
Results
Influence of Ang IV on cell viability and proliferation
Exposure of LNCaP to Ang IV significantly decreased cell proliferation. After the 24 hour-long incubation with Ang IV, the androgen-dependent prostate cancer cells showed lower levels of BrdU incorporation into DNA during the S-phase of the cell cycle. Inhibition of cell proliferation by Ang IV was concentration independent; all results were less than 80% of the control value. The 48-hour incubation with this peptide also attenuated proliferation of LNCaP cells, although only at the lowest tested concentration. Unexpectedly, the highest concentration of Ang IV (5 nM) was found to stimulate cell division (Figure 1(a) ). Ang IV has no effect on DNA synthesis in DU-145 cells, with regard to neither peptide concentration nor time of incubation (Figure 1(b) ). Similar results were obtained from the BrdU assay (24 h) as the MTT assay (24 h) (Figure 1 
Influence of angiotensin receptor blockers on prostate cancer cells
The effects of angiotensin type 1 and 2 receptor antagonists on prostate cancer cell proliferation were investigated by the use of losartan and PD123319, respectively. These receptor inhibitors, when added alone to the culture medium, diminished cell growth in the androgendependent cell line but not the androgen-independent line ( Figure 2 ). As shown in Figure 2 (a), both receptor antagonists negated the inhibitory effect of Ang IV in LNCaP cells. However, only a combination of Ang IV and PD123319 resulted in significant changes, in cell proliferation in comparison with the cells treated with Ang IV alone. There were no differences in the exposure of DU-145 cells to Ang IV or combination Ang IV with inhibitors ( Figure 2(b) ).
Influence of Ang IV on the level of classic angiotensin receptors
As shown in Figure 3 (a), angiotensin receptor subtypes 1 and 2 are present in LNCaP and DU-145 cells. Moreover, the type 1 receptor is predominant over the type 2 in both lines. However, the relationship between AT1 and AT2 was different in androgen-dependent and androgen-independent cell lines. Changes were found in the levels of the classic angiotensin receptors after treatment with Ang IV (5 nM). After 24 h incubation, a large increase of the level of AT1 subtype receptor was observed in DU-145 cells. Exposure of androgen-dependent cells on Ang IV caused a significant decrease of both angiotensin receptor subtypes (Figure 3) . Western blotting and real-time RT-PCR revealed similar changes in angiotensin receptors, before and after Ang IV-treatment. However, the expression of AT1 in DU-145 was very low compared with protein level ( Figure 3B ).
Discussion
A local renin-angiotensin system exists in normal and cancer prostate tissues, including human prostate cancer cell lines. 15 The weakly tumorigenic and non-metastatic prostate cancer cell line LNCaP was used as a model of early stage, androgen-dependent prostate cancer. The aggressive and tumorigenic DU-145 cell line was used as a model of the late, androgen-independent stage of the disease. 16 It was observed that the biological properties of Ang IV were associated with the hormonal status and invasive potential of prostate cancer cells. 16 Siejka et al. 17 demonstrated significant differences between the effects of Ang IV on adrenocortical cell proliferation in ovariectomized and intact rats. Other papers also indicate that the level of the particular elements of RAS and sensitivity of tissues on angiotensins can be modulated by the steroid hormones. [18] [19] [20] Ang IV, a metabolic product of Ang II, could regulate inflammation, cell proliferation and the development of certain cancer types. It was seen to have a stimulatory effect on DNA and RNA synthesis in rat anterior pituitary cells, 21, 22 rabbit cardiac fibroblasts, 23 lung endothelial cells, 24 rat endometrium 25 and rat adrenocortical cells. 26 In addition, it has been found to have antiapoptotic and antiangiogenic properties. [27] [28] [29] In our study, incubation of hormone-dependent prostate cancer cells with Ang IV (24 h) resulted in a significant decrease of cell proliferation at all tested concentrations (Figure 1) . Early investigations show that Ang IV can inhibit PTK activity and LNCaP cell viability. 30 The protein tyrosine kinases are a large enzyme family which plays a significant role in the development of many disease states, including cancer.
On the other hand, Ang IV did not cause any significant effect on DU-145 cells in this study (Figures 1 and 2) . These observations are contradictory to the results presented in the literature. However, Ławnicka et al. 28 suggest that the AT1 receptor expressed in DU-145 cells could be mutated. A mutated version of AT1R, which in general has better abilities to bind to Ang IV (for example N111G AT1), can activate signalling pathways other than the 'wild' AT1R. 31 The binding of Ang IV to angiotensin type 1 and 2 receptors could be inhibited by losartan or PD123319, respectively. First, the receptor inhibitors, when added alone to the culture medium, diminished cell proliferation in LNCaP cells but not in DU-145. This discrepancy between the results of androgen-dependent and androgen-independent prostate cancer lines might reflect variable levels of expression of angiotensin receptors in cells. Another possibility which could be taken into consideration is the involvement of unknown binding sites for losartan and PD123319.
Funao et al. 32 evaluated the effects of telmisartan and other ABRs on cell proliferation in several prostate cancer cell lines. In this study only telmisartan showed promising antiproliferative effects in all prostate cancer cells. However, the authors demonstrated that losartan slightly inhibits LNCaP cell growth and marginally increases the growth of DU-145 cells. Many in vitro and in vivo experiments show conflicting results regarding the use of ABRs for anticancer therapy. This could be due to two reasons: first, one cannot uncritically assume that all drugs in the ABRs class have identical therapeutic action (class effect) and can be used interchangeably, and second, different doses of inhibitors were used at different times of incubation. 33, 34 The molecular mechanism by which Ang IV decreased the proliferation of hormone-dependent prostate cancer cells remains unclear. Ang IV interacts with AT1 and AT2 receptors, but with low affinity. Our study demonstrated that PD123319 partially blocked the inhibitory effect of Ang IV in LNCaP cells ( Figure 2 ). This data suggests that effect of Ang IV on proliferation could be mediated by AT2 receptor. However, we cannot exclude the influence of other receptors specific to this peptide. Recent studies have shown that IRAP might be a high affinity binding site for Ang IV. However, IRAP is associated with stimulation rather than inhibition of cell proliferation. 12, 13 Another mechanism by which Ang IV might exert its cell biological role is based on its partial homology with a region on the hepatocyte growth factor (HGF/c-Met signalling). Highly invasive prostate cancer cells express c-Met at levels well above those observed in less aggressive cancers. What is more, studies have demonstrated that androgen receptor (AR) suppresses c-Met transcription. [35] [36] [37] This could be a reason why this study found different results between androgen-dependent and androgen-independent prostate cancer cell lines after Ang IV treatment.
The classic angiotensin receptors were found in LNCaP and DU-145 cells. Our results show the dominant position of the subtype 1 receptor in both investigated prostate cancer cell lines (Figure 3(a) ). Although the level of AT2 receptor was significantly higher in LNCaP than in DU-145 cell lines (p<0.05), the protein level of the AT1 receptor was found to be similar in both prostate cancer cell lines. Despite this, recent studies note the existence and proportion of classic angiotensin receptors in prostate cancer cell lines. 2, 38, 39 However, some results suggest that the number of passages, culture conditions or even type of medium can influence gene expression. 40 Our data demonstrates, probably for the first time, that Ang IV may be able to modulate the density of AT1 and AT2 receptors. First, treatment of DU-145 cells with Ang IV caused the increase of AT1 receptor level without any consequences for the cell proliferation. Second, a lower distribution of AT1 and AT2 receptors in LNCaP cells was observed after Ang IV treatment. The combination of Ang IV and PD123319 resulted in a significant increase in cell proliferation in comparison with the cells treated with Ang IV alone ( Figure 2 ). These two observations suggest that the increase of proliferation in androgen-dependent prostate cancer cells, after a 48-hour exposure to Ang IV (Figure 1) , may be the consequence of a decrease of the AT2 receptor level. Western blotting and real-time RT-PCR revealed similar dependences in angiotensin receptors, before and after Ang IV-treatment. However, PCR analysis revealed very low expression of AT1 in DU-145 as compared with protein level (Figure 3) .
In summary, Ang IV can regulate cell viability and proliferation in prostate cancer lines. However, significant changes were noted only for the androgen-dependent, poorly-invasive prostate cancer line LNCaP. In androgen independent, aggressive and tumorigenic DU-145 cells, this peptide was ineffective. Hence, the biological properties of Ang IV are probably associated with the invasion potential or hormonal status of examined cells. 16 We also propose that the influence of Ang IV on prostate cells could be based on its ability to modify the levels of angiotensin receptors type 1 and 2.
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